USA:

Europe:

Email:

Consultation

Recombinant Anti-PARK7/DJ-1 Antibody

  • Product Information
  • Description
Catalog: C-FC-4227A
Product Type: FCM Antibody
Size: 50 µL/100 µL
Reactivity: Human
Specificity: Human PARK7/DJ-1
Analysis mode: WB,FCM,ICC/IF,IP
Host: Rabbit
Clonality: Monoclonal
Isotype: IgG
Alternate names: parkinson protein 7
Form: Liquid
Shipping: This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
Purification method: Protein A
Conjugation: Unconjugated
Immunogen: Recombinant Human PARK7 / DJ-1 protein
Buffer: 0.2 μm filtered solution in PBS

Parkinson's disease locus DJ-1 (PARK7) is a differentially expressed transcript. DJ-1 plays a physiologic role in protection of erythroid cells from oxidant damage, a function unmasked in the context of oxidative stress. PARK7 belongs to the peptidase C56 family of proteins. It acts as a positive regulator of androgen receptor-dependent transcription. It may also function as a redox-sensitive chaperone, as a sensor for oxidative stress, and it apparently protects neurons against oxidative stress and cell death. Mutations in the DJ-1 gene are associated with rare forms of autosomal recessive early-onset Parkinson's disease (PD). DJ-1/p53 interactions contribute to apoptosis resistance in clonal myeloid cells and may serve as a prognostic marker in patients with myelodysplastic syndromes (MDS). DJ-1 regulates redox signaling kinase pathways and acts as a transcriptional regulator of antioxidative gene batteries. Therefore, DJ-1 is an important redox-reactive signaling intermediate controlling oxidative stress after ischemia, upon neuroinflammation, and during age-related neurodegenerative processes. Augmenting DJ-1 activity might provide novel approaches to treating chronic neurodegenerative illnesses such as Parkinson's disease and acute damage such as stroke.

Verification Code
top